Evidence map›Paper›PMID 42297808›Full record

Trial reportNature communications2026

Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.

Qihua Zou, Shenrui Bai, Liang Wang, Hongyan Tong, Dongfeng Zeng, Ying Zhao, Yuerong Shuang, Xiaobo Wang, Xiuhua Sun, Zhenya Hong and 23 more

Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05464433 (Open-Label, PhaseIb/Ⅱ Study of Tislelizumab and Mitoxantrone Hydrochloride Liposome Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma（ALLIANCE-022）), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05464433 phase1 / phase2active not recruitingnot on this map

Open-Label, PhaseIb/Ⅱ Study of Tislelizumab and Mitoxantrone Hydrochloride Liposome Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma（ALLIANCE-022）

TypeinterventionalSponsorSun Yat-sen UniversityRan2022 to 2025Enrolled46ConditionsExtranodal Natural Killer T Cell LymphomaArmsTislelizumab combined with Liposomal mitoxantrone hydrochloride, Maintenance of tislelizumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Qihua Zou *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Shenrui Bai *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Liang Wang *Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, P.R. China.ORCID http://orcid.org/0000-0001-6140-914X
Hongyan Tong *Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China.
Dongfeng Zeng *Department of Hematology, Daping Hospital, Army Medical University, Chongqing, P.R. China.
Ying Zhao *Department of Hematology, The First People's Hospital of Foshan, Foshan, P.R. China.
Yuerong ShuangDepartment of Lymphatic and Hematological Oncology, Jiangxi Cancer Hospital, Nanchang, P.R. China.
Xiaobo WangDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, P.R. China.ORCID http://orcid.org/0000-0001-5057-5919
Xiuhua SunDepartment of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, P.R. China.
Zhenya HongDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China.
Zhigang PengDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P.R. China.
Yu YangDepartment of Lymphoma and Head & Neck Tumors, Fujian Cancer Hospital, Fuzhou, P.R. China.
Runhui ZhengDepartment of Hematology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R. China.
Huiqiang HuangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.ORCID http://orcid.org/0000-0002-9090-1907
Jianbo LiuDepartment of Hematology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R. China.
Chunmei YangDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China.
Xi LiDepartment of Hematology, Daping Hospital, Army Medical University, Chongqing, P.R. China.
Xin GaoDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, P.R. China.
Hao XuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China.
Daoguang ChenDepartment of Lymphoma and Head & Neck Tumors, Fujian Cancer Hospital, Fuzhou, P.R. China.
Xiaojie FangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Man NieState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.ORCID http://orcid.org/0000-0001-6109-9268
Jinni WangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Xinna GaoState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Jingjing YeDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, P.R. China.
Wei ZhangDepartment of Hematology, Peking Union Medical College Hospital, Beijing, P.R. China.ORCID http://orcid.org/0000-0001-9489-5965
Jianzhen ShenDepartment of Hematology, Fujian Medical University Union Hospital, Fuzhou, P.R. China.
Rong TaoDepartment of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
Hong CenDepartment of Lymphohematology and Pediatric Oncology, Guangxi Medical University Cancer Hospital, Nanning, P.R. China.
Yuchen ZhangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China. zhangyc1@sysucc.org.cn.ORCID http://orcid.org/0000-0003-3378-1520
Jun CaiState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China. caijun@sysucc.org.cn.ORCID http://orcid.org/0009-0004-5110-1976
Yi XiaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China. xiayi@sysucc.org.cn.ORCID http://orcid.org/0009-0003-1526-1043
Qingqing CaiState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China. caiqq@sysucc.org.cn.ORCID http://orcid.org/0000-0001-5447-3282

Funding

China Postdoctoral Science Foundation 2023M744011Chinese Society of Clinical Oncology (Chinese Society of Clinical Oncology, Beijing Xisike Clinical Oncology Research Foundation) Y-SY2021ZD-0110Guangzhou Science and Technology Program key projects 2024B03J1291National Natural Science Foundation of China (National Science Foundation of China) 8223001National Natural Science Foundation of China (National Science Foundation of China) 82270199National Natural Science Foundation of China (National Science Foundation of China) 82400228National Natural Science Foundation of China (National Science Foundation of China) 82500234National Natural Science Foundation of China (National Science Foundation of China) U24A20680Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) 2024A1515012975
6 · The paper itself

Abstract

Treatment options for relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) remain limited. In this phase 1b/2 trial (NCT05464433), we evaluated the safety and efficacy of liposomal mitoxantrone (Lipo-MIT) plus anti-PD-1 tislelizumab in this setting. During dose escalation, patients received Lipo-MIT (16 or 20 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Extranodal NK-T-CellMitoxantroneAdultAgedFemaleHumansLiposomesMaleMiddle AgedNeoplasm Recurrence, LocalTreatment OutcomeLiposomesMitoxantrone

Identifiers

PMID42297808
PMCPMC13415534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.